Skip to main content

2013 | OriginalPaper | Buchkapitel

29. The Future of Pharmaceutical Manufacturing

verfasst von : Prabir Basu, Thomas Friedli, Daniel Bellm

Erschienen in: Leading Pharmaceutical Operational Excellence

Verlag: Springer Berlin Heidelberg

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

The pharmaceutical industry is definitely a high-tech industry, for its role in discovery of new medicines for the treatment of unmet medical needs. Pharmaceutical manufacturing is complex and sophisticated due to various reasons, but in its current state probably cannot be categorized as really high-tech, too. In fact, pharmaceutical manufacturing was considered as relatively low-tech even by the pharmaceutical companies themselves as recently as in 2002. When ex-FDA commissioner Mark McClellan sought a benchmark for future pharmaceutical manufacturing performance, he looked outside the industry, and challenged Pharma, “You need to improve…Other high-tech industries have achieved enormous productivity gains in manufacturing in the last 25 years. We should expect nothing less from the Pharmaceutical industry.”

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Fußnoten
1
CAMP Member Companies (2002) Quality by design: a challenge to the pharma industry, March.
 
2
Abboud L, Hensley S (2003) New prescription for drug makers: update the plants. Wall Street J, 3 Sept 2003.
 
3
FDA white paper on critical path, Mar 2004.
 
4
Simon HA (1962) The architecture of complexity. Proc Am Philos Soc 106(6):467–482
 
5
Basu PK (1998) Pharmaceutical process development is different. Chem Eng Prog 94:75–82
 
6
Basu PK, Mack RA, Vinson JM (1995) Consider a different approach to pharmaceutical process development. Chem Eng Prog 95:82–90
 
7
Chatterjee S (2011) Role of models in the Quality by Design (QbD) paradigm: a regulatory perspective. AAPS annual meeting, Aug 2011
 
8
FDA (2004) Guidance for industry PAT – a framework for innovative pharmaceutical development, manufacturing, and quality assurance
 
9
Ali Afnan (2011) Real-time release: it’s time for action and not debate. PharmaQbD, 22 Feb 2011
 
10
FDA (2004) Challenges and opportunity on the critical path to new medical products, Mar 2004
 
11
Pagnamenta R (2007) AstraZeneca to outsource manufacturing. Times Online. 17 Sept 2007
 
12
Hensley S (2008) Roche CEO warns big pharma and biotech face rough waters. Health Blog, Wall St J
 
14
Longman R (2008) Arguing by analogy: what pharma can learn from the car business. The RPM report, 20 Nov 2008
 
16
Juran JM (1993) Made in U.S.A.: a renaissance in quality. Har Bus Rev, Jul–Aug
 
17
Pisano G, Shih WC (2009) Restoring American competitiveness. Har Bus Rev, July–Aug
 
18
Wise E (2008) USA Today, 19 Mar 2008
 
19
Woodcock J, Wosinska M (2013) Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther 93(2)
 
20
Moad J (2013) www.​manufacturing-executive.​com. 6 Feb 2013
 
21
Browning LD, Shelter JC (2000) Sematech: saving the US semiconductor industry. Texas A&M University Press, College Station.
 
22
Pittaway L et al (2004) Networking and innovation: a systematic review of the evidence. Int J Manag Rev 5(3–4):137–168
 
23
Pennings JM, Harianto F (2013) Technological networking and innovation implementation. Organ Sci 24:1, Jan–Feb
 
24
Olsen JT (1985) The state of quality in the U.S. Today. Qual Prog 33
 
25
Hayes RH, Wheelwright SC (1984) Restoring our competitive edge. Wiley
 
Metadaten
Titel
The Future of Pharmaceutical Manufacturing
verfasst von
Prabir Basu
Thomas Friedli
Daniel Bellm
Copyright-Jahr
2013
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-642-35161-7_29